Table 2 Blood collections and timings.
Patient | Stage | 1st round chemotherapy (cycles) | Length of time# (weeks) | Concordant mutations in blood vs tissue (%) | Blood tube | Time to process (HH:MM) | Volume (ml) | Nearest CA-125 level (U/ml) |
|---|---|---|---|---|---|---|---|---|
OC1^ | IIIa | Carboplatin/paclitaxel (1) | − 4 | 1 (50%) | EDTA | 3:44 | 5 | – |
OC2 | III | Carboplatin/paclitaxel (6) | − 14 | 0 (0%) | EDTA | 5:11 | 5 | – |
OC3 | IIIc | Carboplatin/paclitaxel (6) | − 67 | 1 (50%) | EDTA | 20:34 | 5 | 13 |
OC4 | IIIc | Carboplatin/paclitaxel (6) | − 142 | 1 (50%) | EDTA | 3:12 | 5 | 142 |
OC5 | IVa | Chemotherapy (Neoadj) (3) | − 30 | N/A (CR*) | EDTA | 4:21 | 5 | 33 |
OC6 | III | Cisplatin/paclitaxel (6) | − 26 | 0 (0%) | EDTA | 4:21 | 5 | 25 |
OC7 | III | Carboplatin/paclitaxel (Neoadj) (3) | 11 | 0 (0%) | EDTA | 23:02 | 5 | – |
OC8 | III | Cisplatin/pegylated liposomal doxorubicin (Neoadj) (4) | − 22 | 0 (0%) | Streck | 19:15 | 4.5 | – |
OC9 | III | Cisplatin/gemcitabine (6) | − 196 | 0 (0%) | EDTA | 2:23 | 5 | – |
OC10 | IIIc | Carboplatin/paclitaxel (6) | − 109 | 1 (100%) | EDTA | 23:04 | 5 | – |
